Literature DB >> 18090405

Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection.

Reto Nüesch1, Jintanat Ananworanich, Preeyaporn Srasuebkul, Ploenchan Chetchotisakd, Wisit Prasithsirikul, Wirat Klinbuayam, Apicha Mahanontharit, Thidarat Jupimai, Kiat Ruxrungtham, Bernard Hirschel.   

Abstract

Thai patients enrolled in STACCATO with HIV/hepatitis B virus (HBV) co-infection and tenofovir/emtricitabine-based antiretroviral therapy (ART) were randomly assigned to continuous treatment or CD4 cell count-guided interruptions. HBV replication was suppressed below detection in 15/16 patients. Structured treatment interruption increased transaminases and HBV viraemia in five of six patients; one flare was severe. Conversion to anti-hepatitis Be occurred with continuous treatment only. Tenofovir/emtricitabine-containing ART is highly effective in controlling chronic HIV/HBV co-infection but treatment should not be interrupted.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18090405     DOI： 10.1097/QAD.0b013e3282f303bf

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  18 in total

Review 1.  Management of the immune reconstitution inflammatory syndrome.

Authors:  Graeme Meintjes; James Scriven; Suzaan Marais
Journal:  Curr HIV/AIDS Rep       Date:  2012-09       Impact factor: 5.071

2.  Prevalence of hepatitis B and hepatitis C coinfections in an adult HIV centre population in Gaborone, Botswana.

Authors:  Premal Patel; Stephanie Davis; Michael Tolle; Vincent Mabikwa; Gabriel Anabwani
Journal:  Am J Trop Med Hyg       Date:  2011-08       Impact factor: 2.345

Review 3.  What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review.

Authors:  Douglas Krakower; Kenneth H Mayer
Journal:  Ann Intern Med       Date:  2012-10-02       Impact factor: 25.391

4.  Development of fatal acute liver failure in HIV-HBV coinfected patients.

Authors:  Albert M Anderson; Marina B Mosunjac; Melody P Palmore; Melissa K Osborn; Andrew J Muir
Journal:  World J Gastroenterol       Date:  2010-08-28       Impact factor: 5.742

5.  Safety of coitally administered tenofovir 1% gel, a vaginal microbicide, in chronic hepatitis B virus carriers: results from the CAPRISA 004 trial.

Authors:  Cheryl Baxter; Nonhlanhla Yende-Zuma; Phindile Tshabalala; Quarraisha Abdool Karim; Salim S Abdool Karim
Journal:  Antiviral Res       Date:  2013-07-04       Impact factor: 5.970

Review 6.  Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review.

Authors:  Hsin-Yun Sun; Wang-Huei Sheng; Mao-Song Tsai; Kuan-Yeh Lee; Sui-Yuan Chang; Chien-Ching Hung
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

7.  Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.

Authors:  Stephan Menne; Scott D Butler; Andrea L George; Ilia A Tochkov; Yuao Zhu; Shelly Xiong; John L Gerin; Paul J Cote; Bud C Tennant
Journal:  Antimicrob Agents Chemother       Date:  2008-08-01       Impact factor: 5.191

Review 8.  Evaluation and treatment of the patient coinfected with hepatitis B and HIV.

Authors:  Ellen Kitchell; Mamta K Jain
Journal:  Curr HIV/AIDS Rep       Date:  2008-08       Impact factor: 5.071

9.  A Review of the 2010 WHO Adult Antiretroviral Therapy Guidelines: Implications and Realities of These Changes for Zambia.

Authors:  Devang M Patel; Crispin Moyo; Christopher M Bositis
Journal:  Med J Zambia       Date:  2010

10.  Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption.

Authors:  Gregory J Dore; Vicente Soriano; Jürgen Rockstroh; Bernd Kupfer; Ellen Tedaldi; Lars Peters; Jacqueline Neuhaus; Massimo Puoti; Marina B Klein; Amanda Mocroft; Bonaventura Clotet; Jens D Lundgren
Journal:  AIDS       Date:  2010-03-27       Impact factor: 4.177
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.